نتایج جستجو برای: 177lu psma

تعداد نتایج: 2383  

Journal: :Molecular cancer therapeutics 2017
Ahmet Krasniqi Matthias D'Huyvetter Catarina Xavier Kevin Van der Jeught Serge Muyldermans José Van Der Heyden Tony Lahoutte Jan Tavernier Nick Devoogdt

Anti-CD20 radioimmunotherapy is an effective approach for therapy of relapsed or refractory CD20pos lymphomas, but faces limitations due to poor tumor penetration and undesirable pharmacokinetics of full antibodies. Camelid single-domain Ab fragments (sdAb) might circumvent some of the limitations of radiolabeled full antibodies. In this study, a set of hCD20-targeting sdAbs was generated, and ...

2017
Lars Henning Schmidt Birthe Heitkötter Arik B Schulze Christoph Schliemann Konrad Steinestel Marcel Trautmann Alessandro Marra Ludger Hillejan Michael Mohr Georg Evers Eva Wardelmann Kambiz Rahbar Dennis Görlich Georg Lenz Wolfgang E Berdel Wolfgang Hartmann Rainer Wiewrodt Sebastian Huss

OBJECTIVES PSMA (prostate-specific membrane antigen) is overexpressed in prostate cancer cells and is reported to be a promising target for antibody-based radioligand therapy in patients with metastasized prostate cancer. Since PSMA expression is not restricted to prostate cancer, the underlying study investigates PSMA expression in non-small cell lung cancer (NSCLC). MATERIAL AND METHODS Imm...

2014
Alexander H Staudacher Fares Al-Ejeh Cara K Fraser Jocelyn M Darby David M Roder Andrew Ruszkiewicz Jim Manavis Michael P Brown

BACKGROUND The lupus-associated (La)-specific murine monoclonal antibody DAB4 (APOMAB®) specifically binds dead cancer cells. Using DAB4, we examined La expression in human lung cancer samples to assess its suitability as a cancer-selective therapeutic target. We evaluated the safety and effectiveness of radioimmunotherapy (RIT) using DAB4 radiolabeled with Lutetium-177 (177Lu) in the murine Le...

2013
Amir Sabet James Nagarajah Ahmet Semih Dogan Hans-Jürgen Biersack Amin Sabet Stefan Guhlke Samer Ezziddin

BACKGROUND Peptide receptor radionuclide therapy (PRRT) with 177Lu-[DOTA0,Tyr3]octreotate (177Lu-octreotate) is generally performed using a fixed activity of 7.4 GBq (200 mCi) per course bound to 180 to 300 μg of the peptide. While this single activity may lead to suboptimal radiation doses in neuroendocrine tumors (NET) with advanced or bulky disease, dose escalation has been withheld due to c...

2015
Hai-long Wang Shao-shan Wang Wen-hui Song Yi Pan Hai-peng Yu Tong-guo Si Yong Liu Xiao-nan Cui Zhi Guo

BACKGROUND Prostate-specific membrane antigen (PSMA) has been found in tumor neovasculature endothelial cells (NECs) of non-prostate cancers and may become the most promising target for anti-tumor therapy. To study the value of PSMA as a potential new target for lung cancer treatment, PSMA expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) tissues and its relatio...

2017
Spencer T. Lake Kirsten L. Greene Antonio C. Westphalen Spencer C. Behr Ronald Zagoria Eric J. Small Peter R. Carroll Thomas A. Hope

BACKGROUND PET/MRI can be used for the detection of disease in biochemical recurrence (BCR) patients imaged with 68Ga-PSMA-11 PET. This study was designed to determine the optimal MRI sequences to localize positive findings on 68Ga-PSMA-11 PET of patients with BCR after definitive therapy. Fifty-five consecutive prostate cancer patients with BCR imaged with 68Ga-PSMA-11 3.0T PET/MRI were retros...

Journal: :International journal of oncology 2012
Kai-Yuan Cao Lin Xu Ding-Mei Zhang Xiao-Ming Zhang Tian Zhang Xia He Zhu Wang Fa-Shen Feng Shao-Peng Qiu Guan-Xin Shen

PSM-E is a newly discovered alternatively spliced variant of prostate-specific membrane antigen (PSMA). In the current study, its role on the proliferation, invasiveness and migration in prostate cancer cell lines was analyzed. PSM-E and PSMA (as a comparison) eukaryotic expression vectors pcDNA3.0/PSM-E and pcDNA3.0/PSMA were constructed, validat...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید